Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12044263 | 0.76 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL12059477 | 0.75 | KMT2A (0.45) | MEN1KMT2ASMN1; SMN2HSD17B10GRIN2D | |
| SCHEMBL12044287 | 0.71 | L3MBTL1 (0.56) | MEN1KMT2ASMN1; SMN2GRIN2DGRIN2C | |
| SCHEMBL12044291 | 0.70 | NPC1 (0.57) | MEN1KMT2ASMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL12044319 | 0.69 | DHPS (0.60) | MEN1KMT2ASMN1; SMN2HSD17B10GRIN2D | |
| SCHEMBL12043935 | 0.68 | GRIN2D (0.79) | MEN1KMT2ASMN1; SMN2GRIN2DGRIN2C | |
| SCHEMBL12044296 | 0.67 | GRIN2D (0.55) | MEN1KMT2ASMN1; SMN2HSD17B10GRIN2D | |
| SCHEMBL12060030 | 0.67 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2HSD17B10GRIN2D | |
| SCHEMBL8945322 | 0.67 | KMT2A (0.85) | MEN1KMT2ASMN1; SMN2HSD17B10MAOA | |
| SCHEMBL9302685 | 0.66 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2HSD17B10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010088408-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | MEN1 4356/4885KMT2A 1870/4885SMN1; SMN2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.